Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This meta-analysis reported that dietary intake of omega-3 or omega-6 fatty acids does not significantly impact prostate cancer risk.

This study reports that adding androgen deprivation therapy to salvage radiation therapy for patients with non-metastatic biochemical recurrence of prostate cancer after radical prostatectomy improves progression-free survival, particularly in those with higher post-prostatectomy PSA levels.

This review discusses various diagnostic and treatment strategies for canine prostate diseases, including pharmacological options and advanced procedures, but reports no new clinical results.

This article discusses the role of 5-alpha-reductase inhibitors in prostate cancer prevention and highlights a medical quandary, but it reports no new clinical findings.

The document does not confirm if radical prostatectomy is the best treatment for locally advanced prostate cancer.

This study found that among male Han Chinese, a higher polygenic risk score was linked to increased risk and poorer treatment outcomes for benign prostatic hyperplasia.

In this study, higher urethral prostate-specific antigen (urPSA) levels in men after radical prostatectomy were associated with higher androgenic alopecia scores and higher postoperative PSA.

Surgery for high-risk prostate cancer is challenging but doesn't lead to more complications, and additional treatment is often needed.

This study found that patients treated with dutasteride were significantly less likely to experience acute urinary retention and prostate-related surgeries compared to those treated with finasteride.

Finasteride reduces the need for prostate surgery but may increase the risk of depression and persistent sexual side effects.

Higher urethral PSA levels after prostate removal surgery may be linked to more hair loss and higher PSA levels post-surgery.

This study found that dutasteride may reduce the likelihood of hospitalization for BPH-related surgery and newly detected prostate cancer, compared to finasteride, and suggests a budgetary benefit.

This study found that finasteride administration for more than one month before TURP surgery significantly reduces blood loss in patients with benign prostatic hyperplasia.

Men with early balding may have a higher risk of prostate issues, and surgery for prostate cancer has a slight survival benefit over radiation.

This study found that prescribing finasteride for two weeks before TURP surgery reduces intraoperative and postoperative blood loss, the rate of blood transfusion, and irrigation fluid usage in patients with BPH.

In this study, significantly fewer men treated with finasteride for moderate to severe BPH symptoms experienced acute urinary retention or required subsequent BPH-related surgery compared to placebo-treated patients.

This retrospective study observed no significant difference in the prevalence of incidental prostate cancer between suprapubic prostatectomy and transurethral prostate resection groups, with most tumors being well differentiated and early-stage.

Finasteride lowers PSA levels in men, certain factors increase testicular cancer risk, and current guidelines for penile cancer may lead to unnecessary surgeries.

CEC levels may be a useful marker for predicting prostate cancer progression.

This review discusses the role of dihydrotestosterone in benign prostatic hyperplasia and reports no new results; the authors highlight 5alpha-reductase inhibitors as a well-established treatment option.

This review re-evaluates the role of Serum Prostate Specific Antigen in prostate cancer diagnosis, suggesting it is most reliable for detecting cancer recurrences after treatment.

The authors concluded that dutasteride is effective and generally safe for managing benign prostatic hyperplasia and may reduce prostate cancer risk.

This case report from the authors highlights a rare diagnosis of high-grade prostate cancer in a 35-year-old man, showing strong functional recovery and no detectable PSA one year after robotic-assisted radical prostatectomy despite the usual onset being significantly later in life.

In this case study, a 3-year-old German Shepherd treated for an enlarged prostate with medication and surgery showed a significant prostate size reduction by 93.9% over 138 days, ruling out neoplastic processes.

This study reports two cases where localized prostate cancer with low PSA levels was incidentally detected through CT scans performed for other medical reasons.

This case report found that a dog's progressive alopecia and prostatitis were caused by ingesting a transdermal estradiol cream, emphasizing the need to identify exogenous estrogen sources during evaluation.

This study found that the epithelial changes in benign prostatic hyperplasia treated with finasteride resembled the pattern of healthy prostates.

This case-control study found that men with earlier onset androgenetic alopecia, particularly frontal balding, may have an increased risk of prostate cancer in a multiethnic veterans cohort.

This study found that while new treatments like Optilume, Rezum, and Aquablation have minimal risks of sexual dysfunction, they offer less improvement in lower urinary tract symptoms compared to traditional surgeries like TURP, though Aquablation does reduce ejaculatory dysfunction more effectively than TURP.

This study found that patients with BPH who received finasteride before TURP experienced reduced intraoperative blood loss and improved quality of life one month after surgery compared to those who did not.